Servier is an international pharmaceutical group governed by a Foundation. With a strong geographic presence and sales of €4.7 billion in 2020 in 150 countries, Servier employs 22,500 people worldwide. Servier is an independent group that invests more than 20% of its originator sales in Research and Development each year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to a dynamic of open and collaborative innovation with academic partners, pharmaceutical groups and biotechnology companies. It also puts the patient's voice at the heart of its activities, from research to support beyond the drug. A leader in cardiology, the Servier group aims to become a recognised and innovative player in oncology. Its growth is based on an ongoing commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier group also offers a range of quality generic medicines covering the majority of diseases. --- If you have experienced or suspect you may be experiencing a health problem related to the use of a Servier drug or any other Servier health product, please visit : https://www.servier.com.pa/content/evento-adverso or directly via mail: farmacovigilancia.centralamerica@servier.com (or phone +507 6625 6119).